Exelixis

EXELIXIS INC

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

ADXN

BYND

CELC

CIIT

DCTH

DGXX

EXEL

FBGL

FCUV

FPAY

NCNA

OLMA

RANI

RAPT

TGHL

VIVK

XRTX

YGMZ

DCTH impulsa el premercado con resultados clínicos positivos del estudio CHOPIN, mientras Beyond Meat y Celcuity lideran las mayores subidas.

Acciones de Delcath Systems (DCTH) suben un 14%; Aquí están 20 acciones que se mueven en el premercado

Exelixis Inc

Exelon Corp

EXELA TECHNOLOGIES INC by Exela Technologies, Inc.

Exela Technologies Inc

EXELA TECHS INC 6% SER B by Exela Technologies, Inc.

Legal

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.   - EXEL

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

Management

SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

AKRO

CRVS

GILD

LEGN

ZLAB

Abivax

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

Caris Life Sciences

CRISPR Therapeutics

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Genmab

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Merus

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Nuvalent

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Summit Therapeutics

TG Therapeutics

Morgan Stanley

RBC Capital

Wells Fargo

Leerink Partners

Goldman Sachs

Comments

Exelixis

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL